Lenalidomide becomes standard of care for multiple myeloma in the maintenance setting
The Journal of Community and Supportive Oncology. 2017 September;15(5): | 10.12788/jcso.0359
August 2, 2018|The Journal of Community and Supportive Oncology
Citation JCSO 2017;15(5):e245-e247
©2017 Frontline Medical Communications
doi https://doi. org/10.12788/jcso.0359
Related article
Immunotherapies shape the treatment landscape for hematologic malignancies
Submit a paper here
,false
